BIRC3 is a novel driver of therapeutic resistance in Glioblastoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Dapeng ^a   Berglund, Anders ^a   Kenchappa, Rajappa S ^a   Forsyth, Peter A ^a   Mule, James J ^a   Etame, Arnold B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRC3 PROTEIN, HUMAN; DACARBAZINE; INHIBITOR OF APOPTOSIS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TEMOZOLOMIDE; UBIQUITIN PROTEIN LIGASE;

ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; RADIATION TOLERANCE; RADIOTHERAPY; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR RECURRENCE; UPREGULATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION TOLERANCE; RADIOTHERAPY; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959036621     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21710     Document Type: Article

References (53)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352, 987-996, doi: 10.1056/NEJMoa043330 (2005).
2. Wong, E. T. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 2572-2578 (1999).
3. Yung, W. K. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British journal of cancer 83, 588-593, doi: 10.1054/bjoc.2000.1316 (2000).
4. Lamborn, K. R. et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncology 10, 162-170, doi: 10.1215/15228517-2007-062 (2008).
5. Ballman, K. V. et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncology 9, 29-38, doi: 10.1215/15228517-2006-025 (2007).
6. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi: 10.1016/j.cell.2011.02.013 (2011).
7. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068, doi: 10.1038/nature07385 (2008).
8. Stegh, A. H. et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes & development 21, 98-111, doi: 10.1101/gad.1480007 (2007).
9. Wagenknecht, B. et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell death and differentiation 6, 370-376, doi: 10.1038/sj.cdd.4400503 (1999).
10. Chen, Z. et al. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochemical and biophysical research communications 264, 847-854, doi: 10.1006/bbrc.1999.1585 (1999).
11. Chakravarti, A. et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 1063-1068 (2002).
12. Miller, L. K. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends in cell biology 9, 323-328 (1999).
13. Crook, N. E., Clem, R. J., Miller, L. K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. Journal of virology 67, 2168-2174 (1993).
14. Liston, P. et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379, 349-353, doi: 10.1038/379349a0 (1996).
15. Altieri, D. C. Survivin and IAP proteins in cell-death mechanisms. The Biochemical journal 430, 199-205, doi: 10.1042/BJ20100814 (2010).
16. Deveraux, Q. L., Reed, J. C. IAP family proteins-suppressors of apoptosis. Genes & development 13, 239-252 (1999).
17. Bertrand, M. J. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30, 789-801, doi: 10.1016/j.immuni.2009.04.011 (2009).
18. Vaux, D. L., Silke, J. Mammalian mitochondrial IAP binding proteins. Biochemical and biophysical research communications 304, 499-504 (2003).
19. Suzuki, Y., Nakabayashi, Y., Takahashi, R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proceedings of the National Academy of Sciences of the United States of America 98, 8662-8667, doi: 10.1073/pnas.161506698 (2001).
20. Suzuki, Y., Nakabayashi, Y., Nakata, K., Reed, J. C., Takahashi, R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes. The Journal of biological chemistry 276, 27058-27063, doi: 10.1074/jbc.M102415200 (2001).
21. Huang, Y. et al. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104, 781-790 (2001).
22. Scott, F. L. et al. XIAP inhibits caspase-3 and-7 using two binding sites: evolutionarily conserved mechanism of IAPs. The EMBO journal 24, 645-655, doi: 10.1038/sj.emboj.7600544 (2005).
23. Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Molecular cell 11, 519-527 (2003).
24. Srinivasula, S. M. et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116, doi: 10.1038/35065125 (2001).
25. Vucic, D., Dixit, V. M., Wertz, I. E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nature reviews. Molecular cell biology 12, 439-452, doi: 10.1038/nrm3143 (2011).
26. Ziegler, D. S. et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro-oncology 13, 820-829, doi: 10.1093/neuonc/nor066 (2011).
27. Ziegler, D. S. et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. The Journal of clinical investigation 118, 3109-3122, doi: 10.1172/JCI34120 (2008).
28. Vogt, P. K., Hart, J. R. PI3K and STAT3: a new alliance. Cancer Discov 1, 481-486, doi: 10.1158/2159-8290.CD-11-0218 (2011).
29. Lee, E. S., Ko, K. K., Joe, Y. A., Kang, S. G., Hong, Y. K. Inhibition of STAT3 reverses drug resistance acquired in temozolomideresistant human glioma cells. Oncology letters 2, 115-121, doi: 10.3892/ol.2010.210 (2011).
30. Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., Loeffler, J. S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RASdependent manner. Cancer research 62, 4307-4315 (2002).
31. Wu, H. H. et al. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 5200-5210, doi: 10.1158/1078-0432.CCR-10-0020 (2010).
32. Koide, M. et al. Apoptosis regulator through modulating IAP expression (ARIA) controls the PI3K/Akt pathway in endothelial and endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 108, 9472-9477, doi: 10.1073/pnas.1101296108 (2011).
33. Huang, P. H. et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 104, 12867-12872, doi: 10.1073/pnas.0705158104 (2007).
34. Timofeeva, O. A. et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proceedings of the National Academy of Sciences of the United States of America 110, 1267-1272, doi: 10.1073/pnas.1211805110 (2013).
35. de Groot, J. et al. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 3, 1036-1048 (2012).
36. Kohsaka, S. et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Molecular cancer therapeutics 11, 1289-1299, doi: 10.1158/1535-7163.MCT-11-0801 (2012).
37. Brantley, E. C. et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clinical cancer research: an official journal of the American Association for Cancer Research 14, 4694-4704, doi: 10.1158/1078-0432.CCR-08-0618 (2008).
38. Jiang, H. et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro-oncology 15, 775-782, doi: 10.1093/neuonc/not027 (2013).
39. Vellanki, S. H. et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 11, 743-752 (2009).
40. Bhattacharya, S., Ray, R. M., Johnson, L. R. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. The Biochemical journal 392, 335-344, doi: 10.1042/BJ20050465 (2005).
41. Zhang, X. et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer research 73, 1922-1933, doi: 10.1158/0008-5472.CAN-12-3175 (2013).
42. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine 352, 997-1003, doi: 10.1056/NEJMoa043331 (2005).
43. Guvenc, H. et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 631-642, doi: 10.1158/1078-0432.CCR-12-0647 (2013).
44. Gu, L. et al. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer cell 15, 363-375, doi: 10.1016/j. ccr.2009.03.002 (2009).
45. Yang, W., Cooke, M., Duckett, C. S., Yang, X., Dorsey, J. F. Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells. Cell cycle 13, 992-1005, doi: 10.4161/cc.27880 (2014).
46. Mahoney, D. J. et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proceedings of the National Academy of Sciences of the United States of America 105, 11778-11783, doi: 10.1073/pnas.0711122105 (2008).
47. Rothe, M., Pan, M. G., Henzel, W. J., Ayres, T. M., Goeddel, D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83, 1243-1252 (1995).
48. Shu, H. B., Takeuchi, M., Goeddel, D. V. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proceedings of the National Academy of Sciences of the United States of America 93, 13973-13978 (1996).
49. Zarnegar, B. J. et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nature immunology 9, 1371-1378, doi: 10.1038/ni.1676 (2008).
50. Zhao, X. et al. An NF-kappaB p65-cIAP2 link is necessary for mediating resistance to TNF-alpha induced cell death in gliomas. Journal of neuro-oncology 102, 367-381, doi: 10.1007/s11060-010-0346-y (2011).
51. Wagner, L. et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1-and NF-kappaBdependent manner. Oncogene 32, 988-997, doi: 10.1038/onc.2012.108 (2013).
52. Berger, R. et al. NF-kappaB is required for Smac mimetic-mediated sensitization of glioblastoma cells for gamma-irradiationinduced apoptosis. Molecular cancer therapeutics 10, 1867-1875, doi: 10.1158/1535-7163.MCT-11-0218 (2011).
53. Fulda, S., Wick, W., Weller, M., Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature medicine 8, 808-815, doi: 10.1038/nm735 (2002).